Acrivon Therapeutics (ACRV) vs ProMIS Neurosciences (PMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Acrivon Therapeutics (ACRV) has outperformed ProMIS Neurosciences (PMN) over the past year, losing 0.5% versus a loss of 35.8%. ProMIS Neurosciences is the larger company by market cap ($82.1 million vs $80.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRV | PMN |
|---|---|---|
| Share price | $1.87 | $9.15 |
| Market cap | $80.14M | $82.05M |
| 1-day change | -0.53% | +0.33% |
| YTD return | -22.41% | +33.97% |
| 1-year return | -0.53% | -35.79% |
| 5-year return | — | -95.93% |
| EPS (TTM) | $-1.88 | $-11.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.56 | $27.40 |
| 52-week low | $1.27 | $6.27 |
| Distance from 52-week high | -47.47% | -66.61% |
| Analyst consensus | none | none |
| Avg. price target upside | +514.97% | +365.68% |
| Average volume | 356.18K | 83.76K |
| Shares outstanding | 42.85M | 8.97M |
| Employees | 74 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRV has outperformed PMN by 35.3 percentage points over the past year.
About Acrivon Therapeutics
ACRV stock →Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
About ProMIS Neurosciences
PMN stock →ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
ACRV vs PMN FAQ
Which is bigger, Acrivon Therapeutics or ProMIS Neurosciences?
ProMIS Neurosciences (PMN) is larger, with a market capitalization of $82.05M compared with $80.14M for Acrivon Therapeutics (ACRV).
Which stock has performed better over the past year, ACRV or PMN?
ACRV returned -0.53% over the past 12 months, compared with -35.79% for PMN (price return, excluding dividends). Past performance does not predict future results.
Are Acrivon Therapeutics and ProMIS Neurosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.